J M Lange

Summary

Affiliation: Academic Medical Center
Country: The Netherlands

Publications

  1. pmc Development and evaluation of a patient centered cardiovascular health education program for insured patients in rural Nigeria (QUICK - II)
    Aina Olufemi Odusola
    Dept of Global Health, Academic Medical Center, University of Amsterdam, Amsterdam, 1105 BM, The Netherlands
    BMC Public Health 11:171. 2011
  2. pmc Cardiovascular disease prevention in rural Nigeria in the context of a community based health insurance scheme: QUality Improvement Cardiovascular care Kwara-I (QUICK-I)
    Marleen Hendriks
    Dept of Global Health, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    BMC Public Health 11:186. 2011
  3. pmc Methodological standards in non-inferiority AIDS trials: moving from adherence to compliance: response
    Frank van Leth
    BMC Med Res Methodol 7:14. 2007
  4. ncbi request reprint What policymakers should know about drug resistance and adherence in the context of scaling-up treatment of HIV infection
    Joep M A Lange
    International AIDS Society and International Antiviral Therapy Evaluation Center, Academic Medical Center, University of Amsterdam, The Netherlands
    AIDS 18:S69-74. 2004
  5. ncbi request reprint Efficacy and durability of nevirapine in antiretroviral drug näive patients
    Joep M A Lange
    Department of Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    J Acquir Immune Defic Syndr 34:S40-52. 2003
  6. pmc We must not let protestors derail trials of pre-exposure prophylaxis for HIV
    Joep M A Lange
    Center for Poverty related Communicable Diseases, Academic Medical Center, University of Amsterdam, The Netherlands
    PLoS Med 2:e248. 2005
  7. ncbi request reprint A rational approach to the selection and sequencing of nucleoside/nucleotide analogues: a new paradigm
    J Lange
    Academic Medical Centre, Amsterdam, The Netherlands
    Antivir Ther 6:45-54. 2001
  8. ncbi request reprint The power of simplicity
    J Lange
    National AIDS Therapy Evaluation Centre, Academic Medical Centre, Amsterdam, The Netherlands
    Int J STD AIDS 14:15-9. 2003
  9. ncbi request reprint Strategies for rescue therapy
    J M Lange
    National AIDS Therapy Evaluation Center, Academic Medical Center, University of Amsterdam, The Netherlands
    Antivir Ther 3:75-7. 1998
  10. ncbi request reprint Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study
    P T Nieuwkerk
    Department of Medical Psychology J4 410, Academic Medical Center, PO Box 22700, 1100 DE Amsterdam, The Netherlands
    Arch Intern Med 161:1962-8. 2001

Detail Information

Publications103 found, 100 shown here

  1. pmc Development and evaluation of a patient centered cardiovascular health education program for insured patients in rural Nigeria (QUICK - II)
    Aina Olufemi Odusola
    Dept of Global Health, Academic Medical Center, University of Amsterdam, Amsterdam, 1105 BM, The Netherlands
    BMC Public Health 11:171. 2011
    ....
  2. pmc Cardiovascular disease prevention in rural Nigeria in the context of a community based health insurance scheme: QUality Improvement Cardiovascular care Kwara-I (QUICK-I)
    Marleen Hendriks
    Dept of Global Health, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    BMC Public Health 11:186. 2011
    ....
  3. pmc Methodological standards in non-inferiority AIDS trials: moving from adherence to compliance: response
    Frank van Leth
    BMC Med Res Methodol 7:14. 2007
  4. ncbi request reprint What policymakers should know about drug resistance and adherence in the context of scaling-up treatment of HIV infection
    Joep M A Lange
    International AIDS Society and International Antiviral Therapy Evaluation Center, Academic Medical Center, University of Amsterdam, The Netherlands
    AIDS 18:S69-74. 2004
    ..Experience in developing countries also suggests that greater treatment access will help alleviate HIV-related stigma and provide major new incentives for individuals to learn their serostatus, thus strengthening prevention efforts...
  5. ncbi request reprint Efficacy and durability of nevirapine in antiretroviral drug näive patients
    Joep M A Lange
    Department of Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    J Acquir Immune Defic Syndr 34:S40-52. 2003
    ..All four arms of the study include a backbone of stavudine and lamivudine...
  6. pmc We must not let protestors derail trials of pre-exposure prophylaxis for HIV
    Joep M A Lange
    Center for Poverty related Communicable Diseases, Academic Medical Center, University of Amsterdam, The Netherlands
    PLoS Med 2:e248. 2005
  7. ncbi request reprint A rational approach to the selection and sequencing of nucleoside/nucleotide analogues: a new paradigm
    J Lange
    Academic Medical Centre, Amsterdam, The Netherlands
    Antivir Ther 6:45-54. 2001
    ..However, more clinical investigation is required into both the performance of alternative first-line..
  8. ncbi request reprint The power of simplicity
    J Lange
    National AIDS Therapy Evaluation Centre, Academic Medical Centre, Amsterdam, The Netherlands
    Int J STD AIDS 14:15-9. 2003
    ..Didanosine is effective in patients failing lamivudine therapy who have the M184V mutation. Enteric-coated didanosine is also an important component of early therapy, due to its potency and ease of administration...
  9. ncbi request reprint Strategies for rescue therapy
    J M Lange
    National AIDS Therapy Evaluation Center, Academic Medical Center, University of Amsterdam, The Netherlands
    Antivir Ther 3:75-7. 1998
    ..Rescue or salvage therapy refers to therapy after everything else has failed. Issues related to rescue therapy for HIV-positive subjects include drug holidays, drug recycling and the potential for new drugs in this setting...
  10. ncbi request reprint Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study
    P T Nieuwkerk
    Department of Medical Psychology J4 410, Academic Medical Center, PO Box 22700, 1100 DE Amsterdam, The Netherlands
    Arch Intern Med 161:1962-8. 2001
    ..We investigated adherence to HAART among patients in a clinical cohort study...
  11. ncbi request reprint Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy
    J M Prins
    Department of Internal Medicine, Tropical Medicine, and AIDS, Academic Medical Center, University of Amsterdam, The Netherlands
    AIDS 13:2405-10. 1999
    ..This is a major barrier for the eradication of HIV by antiretroviral agents alone. Activation of these cells in the presence of antiretroviral therapy might be a strategy to increase the turnover rate of this reservoir...
  12. ncbi request reprint Quantitative pp65-antigenemia assay for the prediction of human cytomegalovirus disease in HIV-infected patients
    B S Blank
    National AIDS Therapy Evaluation Center NATEC, Department of Internal Medicine, Amsterdam, The Netherlands
    AIDS 13:2533-9. 1999
    ..To evaluate the ability of a quantified pp65-antigenemia assay to predict the development of human cytomegalovirus (HCMV) disease in patients with an advanced HIV infection...
  13. ncbi request reprint Improvement of chronic diarrhoea in patients with advanced HIV-1 infection during potent antiretroviral therapy
    N A Foudraine
    Municipal Health Service, Department of Public Health and Environment, Amsterdam, The Netherlands
    AIDS 12:35-41. 1998
    ..A substantial number of patients with advanced HIV infection suffer from intractable diarrhoea. The aim of this study was to evaluate whether potent antiretroviral therapy could alleviate such diarrhoea...
  14. ncbi request reprint Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial
    N A Foudraine
    Municipal Health Service, Department of Public Health and Environment, Amsterdam, The Netherlands
    Antivir Ther 6:55-62. 2001
    ..To assess CSF concentrations of indinavir at week 48...
  15. ncbi request reprint Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection
    A I Veldkamp
    Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands
    J Chromatogr B Biomed Sci Appl 734:55-61. 1999
    ..This validated assay is suited for use in pharmacokinetic studies with efavirenz and can readily be implemented in the setting of a hospital laboratory for the monitoring of efavirenz concentrations...
  16. ncbi request reprint Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals
    A I Veldkamp
    Departments of Pharmacy and Pharmacology and Internal Medicine, Slotervaart Hospital, Amsterdam, The Netherlands
    J Acquir Immune Defic Syndr 27:344-9. 2001
    ....
  17. ncbi request reprint Decline of antibody reactivity to outer viral core protein p17 is an earlier serological marker of disease progression in human immunodeficiency virus infection than anti-p24 decline
    J M Lange
    Department of Virology, Academic Medical Centre, University of Amsterdam, The Netherlands
    AIDS 1:155-9. 1987
    ....
  18. ncbi request reprint Long-term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection
    P T Nieuwkerk
    Department of Medical Psychology, Academic Medical Center, Amsterdam, The Netherlands
    AIDS 15:1985-91. 2001
    ....
  19. ncbi request reprint Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection
    M H Godfried
    Department of Internal Medicine, University of Amsterdam, The Netherlands
    J Acquir Immune Defic Syndr Hum Retrovirol 10:531-9. 1995
    ..Thus, in contrast to CD4+ counts and neopterin levels, sTNFR concentrations, especially those of the type II STNFR, appear to be valuable surrogate markers for monitoring the efficacy of ZDV treatment in asymptomatic HIV-1 infection...
  20. ncbi request reprint High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals
    A I Veldkamp
    Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands
    AIDS 15:1089-95. 2001
    ..These findings suggest that optimization of nevirapine concentration might be used as a tool to improve virological outcome in (antiretroviral-naive) patients treated with nevirapine...
  21. ncbi request reprint Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons
    F W Wit
    National AIDS Therapy Evaluation Center NATEC, Department of Infectious Diseases, Tropical Medicine, and AIDS, Division of Internal Medicine, Academic Medical Center, 1105 AZ Amsterdam, The Netherlands
    J Infect Dis 179:790-8. 1999
    ..This was significantly more frequent for regimens containing saquinavir (62%; 27% for virologic failure) or ritonavir (64%; 55% for intolerance) as single protease inhibitor...
  22. ncbi request reprint Limited sampling strategies for the estimation of the systemic exposure to the HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapine
    A I Veldkamp
    Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands
    Ther Drug Monit 23:606-11. 2001
    ..The authors therefore conclude that less intensive sampling (i.e., a single sample) can readily be used to assess the AUC 12h of nevirapine when used in a dosage of 200 mg twice daily...
  23. ncbi request reprint Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detection
    A I Veldkamp
    Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands
    J Chromatogr B Biomed Sci Appl 727:151-7. 1999
    ..This validated assay is suited for use in pharmacokinetic studies with delavirdine and can readily be implemented in the setting of a hospital laboratory for the monitoring of delavirdine concentrations...
  24. ncbi request reprint Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1
    R M van Praag
    National AIDS Therapy Evaluation Center, Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, University of Amsterdam, Amsterdam, The Netherlands
    Clin Infect Dis 33:e91-2. 2001
    ..To our knowledge, there are currently no available data on the penetration of the nucleoside analogue abacavir into the male genital tract. Our report shows that abacavir has good penetration into the male genital tract...
  25. ncbi request reprint Numbers of CD4+ cells and the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men
    F de Wolf
    Department of Virology, University of Amsterdam, The Netherlands
    J Infect Dis 158:615-22. 1988
    ..Four more cases of AIDS developed among the antigen-negative, core antibody-positive men with low CD4+ cell counts. Only one patient with AIDS escaped detection by using these three markers...
  26. ncbi request reprint Saliva as an alternative body fluid for therapeutic drug monitoring of the nonnucleoside reverse transcription inhibitor nevirapine
    R P van Heeswijk
    Department of Pharmacy and Pharmacology and Internal Medicine, Slotervaart Hospital, Amsterdam, The Netherlands
    Ther Drug Monit 23:255-8. 2001
    ..This relation has been validated prospectively, and the prediction of plasma concentrations was accurate and precise. Therefore, the authors conclude that saliva can be a useful body fluid for therapeutic drug monitoring of nevirapine...
  27. ncbi request reprint A comparison of serum HIV-1 RNA levels as measured by two quantitative assays in zidovudine-treated, asymptomatic, HIV-infected individuals
    G J Weverling
    National AIDS Therapy Evaluation Center, Department of Clinical Epidemiology and Biostatistics, University of Amsterdam, The Netherlands
    Antivir Ther 1:255-63. 1996
    ..These differences should be considered in interpreting analyses of clinical trials and relationships between HIV-1 RNA level and clinical outcome, as well as in the use of RNA level in the management of HIV-infected patients...
  28. ncbi request reprint Replication of a pre-existing resistant HIV-1 subpopulation in vivo after introduction of a strong selective drug pressure
    M D de Jong
    Department of Virology, Academic Medical Centre, University of Amsterdam, The Netherlands
    Antivir Ther 1:33-41. 1996
    ..The extensive repercussions for subsequent treatment of even a minor subpopulation of naturally occurring drug-resistant variants observed in this study must be considered in future therapeutic strategies...
  29. ncbi request reprint Results of long-term follow-up of HIV-infected patients treated with lamivudine monotherapy, followed by a combination of lamivudine and zidovudine
    R van Leeuwen
    National AIDS Therapy Evaluation Center, Department of Medicine, University of Amsterdam, The Netherlands
    Antivir Ther 2:79-90. 1997
    ..In conclusion, zidovudine was found to be effective in patients who have been treated with lamivudine. The study stresses the need to further define the mechanisms underlying this prolonged antiviral effect...
  30. pmc Failure to maintain high-dose treatment regimens during long-term use of zidovudine in patients with symptomatic human immunodeficiency virus type 1 infection
    R van Leeuwen
    Department of Internal Medicine AIDS Unit, University of Amsterdam, The Netherlands
    Genitourin Med 66:418-22. 1990
    ....
  31. ncbi request reprint Dose-finding study of a once-daily indinavir/ritonavir regimen
    P W Hugen
    Department of Clinical Pharmacy Department of General Internal Medicine, University Medical Centre St Radboud Nijmegen and National AIDS Therapy Evaluation Centre, Academical Medical Centre, Amsterdam, The Netherlands
    J Acquir Immune Defic Syndr 25:236-45. 2000
    ..Steady-state pharmacokinetic data of once-daily IDV/RTV regimens in HIV-infected patients are warranted...
  32. ncbi request reprint Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways
    M van der Valk
    National AIDS Therapy Evaluation Center and Department of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Center, Amsterdam, The Netherlands
    AIDS 15:2093-100. 2001
    ..We assessed glucose disposal and its pathways, glucose production, plasma free fatty acid (FFA) levels, and the degree to which these parameters could be suppressed by insulin...
  33. ncbi request reprint T cell expansions in lymph nodes and peripheral blood in HIV-1-infected individuals: effect of antiretroviral therapy
    S Kostense
    Department of Clinical Viro-Immunology, CLB, Amsterdam, The Netherlands
    AIDS 15:1097-107. 2001
    ..Decreased immune activation and possibly naive T cell regeneration subsequently decreased clonal expansions and perturbations in the CD8 TCR repertoire...
  34. ncbi request reprint Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience
    R P van Heeswijk
    Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands
    Antivir Ther 6:201-29. 2001
    ..This review covers combinations of saquinavir, indinavir, nelfinavir, amprenavir and lopinavir with different doses of ritonavir, as well as the combinations of saquinavir and indinavir with nelfinavir...
  35. ncbi request reprint [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection]
    F van Leth
    Academisch Medisch Centrum Universiteit van Amsterdam, afd Inwen dige Geneeskunde, onderafd Infectieziekten, Tropische Geneeskunde en Aids, Center for Poverty related Communicable Diseases, Amsterdam
    Ned Tijdschr Geneeskd 150:1719-22. 2006
    ..The choice between the two drugs can be tailored to the needs of the patient. The rapid selection ofNNRTI-resistant HIV-I strains during the sub-optimal use of nevirapine and efavirenz demands the development of new NNRTIs...
  36. ncbi request reprint Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains
    J Goudsmit
    Department of Human Retrovirology, Academic Medical Centre, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands
    AIDS 15:2293-301. 2001
    ....
  37. ncbi request reprint Effects of recombinant human granulocyte colony-stimulating factor on leucopenia in zidovudine-treated patients with AIDS and AIDS related complex, a phase I/II study
    P A van der Wouw
    Department of Internal Medicine AIDS Unit, University of Amsterdam, The Netherlands
    Br J Haematol 78:319-24. 1991
    ..We conclude that G-CSF increases the number of circulating neutrophilic granulocytes in zidovudine-treated patients at relatively low doses and with few side-effects...
  38. ncbi request reprint A study of the reliability, validity and responsiveness of the HIV overview of problems evaluation system (HOPES) in assessing the quality of life of patients with AIDS and symptomatic HIV infection
    J B de Boer
    Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Qual Life Res 5:339-47. 1996
    ..This study provides further evidence of the reliability and validity of the HOPES and shows that this instrument is responsive to changes in CD4 cell counts...
  39. ncbi request reprint Autoimmunity against blood cells in human immunodeficiency-virus (HIV) infection
    J van der Lelie
    Department of Haematology, University of Amsterdam, The Netherlands
    Br J Haematol 67:109-14. 1987
    ..There was no relation between the serological findings and the platelet and granulocyte counts. We conclude that autoantibodies against platelets and granulocytes are common in patients with AIDS and those at risk...
  40. ncbi request reprint Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine
    F W Wit
    International Antiviral Therapy Evaluation Center, Department of Human Retrovirology and Department of Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands
    AIDS 15:2423-9. 2001
    ..Short-term therapy with prednisolone did not prevent HSR in patients using ABC with or without NVP...
  41. pmc Pharmacokinetic profiles of nevirapine and indinavir in various fractions of seminal plasma
    R M van Praag
    National AIDS Therapy Evaluation Center, Department of Internal Medicine, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Antimicrob Agents Chemother 45:2902-7. 2001
    ..Furthermore, our data suggest that NVP and IDV achieve therapeutic concentrations in both the testes and prostate and the seminal vesicles throughout the dosing interval...
  42. ncbi request reprint OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion
    R M van Praag
    Department of Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands
    J Clin Immunol 21:218-26. 2001
    ..CD8+ cells were also depleted in the blood, but less severely in lymph nodes, and returned to baseline levels within several weeks...
  43. ncbi request reprint [Coinfection with hepatitis C virus and HIV]
    Th A Ruys
    afd Inwendige Geneeskunde, onderafd Infectieziekten, Tropische Geneeskunde en Aids, Academisch Medisch Centrum Universiteit van Amsterdam, Postbus 22 660, 1100 DD Amsterdam
    Ned Tijdschr Geneeskd 147:2056-60. 2003
    ..A combination of ribavirin with zidovudine or didanosine is best avoided. Developments being made with new classes of drugs, such as HCV-specific protease inhibitors and polymerase inhibitors, seem promising...
  44. pmc Value of different assays for detection of human cytomegalovirus (HCMV) in predicting the development of HCMV disease in human immunodeficiency virus-infected patients
    B S Blank
    National AIDS Therapy Evaluation Center, Department of Internal Medicine, Academic Medical Center, University of Amsterdam, The Netherlands
    J Clin Microbiol 38:563-9. 2000
    ..In conclusion, virological screening by these qualitative assays for detection of HCMV is of limited value for prediction of the development of HCMV disease in HIV-infected patients...
  45. ncbi request reprint Persistent human immunodeficiency virus type 1 antigenemia in children correlates with disease progression
    L G Epstein
    Virology Department, Academic Medical Center, Amsterdam, The Netherlands
    Pediatrics 82:919-24. 1988
    ..These data suggest that HIV-Ag probably does not cross the placenta and that the detection of free HIV-Ag in the offspring of a HIV-1 infected mother most likely indicates viral infection.(ABSTRACT TRUNCATED AT 250 WORDS)..
  46. ncbi request reprint Short communication: No detrimental immunological effects of mycophenolate mofetil and HAART in treatment-naive acute and chronic HIV-1-infected patients
    Nienke Vrisekoop
    Department of Clinical Viro Immunology, Sanquin Research and Landsteiner Laboratory of the Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    AIDS Res Hum Retroviruses 21:991-6. 2005
    ..Still, there was no evidence for detrimental effects of treatment with mycophenolate mofetil in addition to HAART on CD4+ T cell reconstitution or HIV-specific immunity...
  47. ncbi request reprint Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy
    Frank van Leth
    International Antiviral Therapy Evaluation Center, Department of Internal Medicine, Academic Medical Center, University of Amsterdam, The Netherlands
    J Acquir Immune Defic Syndr 38:296-300. 2005
    ..We compared the rate of pVL decline in patients starting ART with nevirapine (NVP), efavirenz (EFV), or both drugs combined in addition to lamivudine (3TC) and stavudine (d4T)...
  48. ncbi request reprint Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study
    Bregt S Kappelhoff
    Slotervaart Hospital, Department of Pharmacy and Pharmacology, Amsterdam, The Netherlands
    HIV Clin Trials 6:254-61. 2005
    ..As part of the large international, randomized 2NN trial, the pharmacokinetics of nevirapine in once-daily 400 mg and twice-daily 200 mg dosing regimens were investigated...
  49. ncbi request reprint Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients
    Reshma Saskia Autar
    The HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, 104 Rajdumri Road, 10330 Pathumwan, Bangkok, Thailand
    J Antimicrob Chemother 56:908-13. 2005
    ..Differential exposure to saquinavir/ritonavir may lead to therapy failure. The objective was to identify factors that influence variability of saquinavir/ritonavir plasma concentrations...
  50. ncbi request reprint Protease inhibitors and non-nucleoside reverse transcriptase inhibitors have a comparable effect on the CD4 cell change after switching to tenofovir-based regimens
    Frank van Leth
    AIDS 19:1722-3. 2005
  51. ncbi request reprint Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy
    Erwan Piriou
    Department of Clinical Viro Immunology, Sanquin Research at CLB and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    J Immunol 175:2010-7. 2005
    ..In conclusion, long-term HAART does not alter the EBV DNA load, but does lead to a restoration of EBNA1-specific T cell responses, which might allow better control of EBV-infected cells when applied early enough during HIV infection...
  52. ncbi request reprint Analysis of the effect of highly active antiretroviral therapy during acute HIV-1 infection on HIV-specific CD4 T cell functions
    Christine A Jansen
    Department of Clinical Viro Immunology, Sanquin Research and Landsteiner Laboratory, University of Amsterdam, The Netherlands
    AIDS 19:1145-54. 2005
    ..It has been reported that antiretroviral therapy (HAART) during acute HIV-1 infection may rescue HIV-1-specific CD4 T cell responses...
  53. ncbi request reprint GB virus C coinfection and HIV-1 disease progression: The Amsterdam Cohort Study
    Akke K van der Bij
    Department of HIV and STD Research, Cluster of Infectious Diseases, Municipal Health Service of Amsterdam, The Netherlands
    J Infect Dis 191:678-85. 2005
    ....
  54. ncbi request reprint Cytomegalovirus rather than HIV triggers the outgrowth of effector CD8+CD45RA+CD27- T cells in HIV-1-infected children
    Vincent Bekker
    Emma Children s Hospital, Sanquin Research and Landsteiner Laboratory, Academic Medical Center fInternational Antiviral Therapy Evaluation Center, Amsterdam, The Netherlands
    AIDS 19:1025-34. 2005
    ..To analyse the effect of viral coinfections on immune reconstitution in HIV-1-infected children (< 18 years) taking highly active antiretroviral therapy (HAART)...
  55. ncbi request reprint Viral dynamics after starting first-line HAART in HIV-1-infected children
    Vincent Bekker
    Emma Children s Hospital, Academic Medical Center, The Netherlands
    AIDS 20:517-23. 2006
    ..Therefore viral decay and time to reach a pVL of < 400 copies/ml during the first weeks after starting HAART were studied in a cohort of HIV-1-infected children...
  56. ncbi request reprint Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort
    Henriette J Scherpbier
    Emma Children s Hospital, Academic Medical Center, Amsterdam, The Netherlands
    Pediatrics 117:e528-36. 2006
    ..We sought to provide long-term data on the clinical, immunologic, and virologic response to highly active antiretroviral therapy in infants and children who are naive to protease inhibitors...
  57. doi request reprint Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study
    Ferdinand W N M Wit
    Center for Poverty related Communicable Diseases, and Department of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Clin Infect Dis 46:933-40. 2008
    ..It is unclear whether these guidelines also apply to treatment-experienced patients switching to NVP-based combination therapy...
  58. ncbi request reprint Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy: a substudy from the Antiretroviral Regimen Evaluation Study (ARES)
    Selwyn H Lowe
    International Antiviral Therapy Evaluation Center IATEC, Amsterdam, The Netherlands
    HIV Clin Trials 8:337-44. 2007
    ....
  59. ncbi request reprint Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen
    Selwyn H Lowe
    Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Ther Drug Monit 29:566-70. 2007
    ..The authors conclude that ddI and TFV penetrate well into seminal plasma and that the reduced sperm motility deserves further study...
  60. ncbi request reprint Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients
    Reshma Saskia Autar
    HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Thai Red Cross Aids Research Centre TRCARC, 104 Rajdumri Road, 10330 Pathumwan, Bangkok, Thailand
    AIDS 21:1535-9. 2007
    ..However, toxicity, storage conditions and high costs of antiretroviral treatment may necessitate interruption of ritonavir. Ketoconazole was investigated as a potential booster of once-daily (o.d.) saquinavir...
  61. ncbi request reprint Efavirenz: a review
    Saskia M E Vrouenraets
    IATEC, Pietersbergweg 9, 1105 BM Amsterdam, The Netherlands
    Expert Opin Pharmacother 8:851-71. 2007
    ..This review outlines important and recent pharmacological and clinical data, which explain why efavirenz became a component of preferred treatment regimens today...
  62. ncbi request reprint CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater
    Luuk Gras
    HIV Monitoring Foundation, Amsterdam, The Netherlands
    J Acquir Immune Defic Syndr 45:183-92. 2007
    ..CD4 cell count changes in therapy-naive patients were investigated during 7 years of highly active antiretroviral therapy (HAART) in an observational cohort...
  63. ncbi request reprint Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens
    Stephen J Kerr
    The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    J Int Assoc Physicians AIDS Care (Chic) 6:36-46. 2007
    ..Non-stavudine-containing non-boosted protease-inhibitor-based highly active antiretroviral treatment regimens had the least association with dyslipidemia...
  64. ncbi request reprint Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen
    Henriette J Scherpbier
    Emma Children s Hospital, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Pediatrics 119:e705-15. 2007
    ....
  65. ncbi request reprint Antiviral activity of HIV type 1 protease inhibitors nelfinavir and indinavir in vivo is not influenced by P-glycoprotein activity on CD4+ T cells
    Sanjay U C Sankatsing
    International Antiviral Therapy Evaluation Center, Amsterdam, The Netherlands
    AIDS Res Hum Retroviruses 23:19-27. 2007
    ..Therefore we conclude that the potential efflux function of P-gp on PIs may be clinically less relevant than the effect of P-gp on intracellular HIV-1 replication...
  66. ncbi request reprint No virological failure in semen during properly suppressive antiretroviral therapy despite subtherapeutic local drug concentrations
    Selwyn H Lowe
    Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Centre, University of Amsterdam, Amsterdam
    HIV Clin Trials 7:285-90. 2006
    ..The aim of the study was to investigate whether drug resistance occurs earlier in seminal than in blood plasma with the use of such HAART regimens, of which only the two NRTIs achieve therapeutic concentrations in seminal plasma...
  67. ncbi request reprint Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN)
    Katalin Pogany
    Department of Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands
    J Acquir Immune Defic Syndr 44:395-400. 2007
    ..To evaluate the safety and efficacy of discontinuing highly active antiretroviral therapy (HAART) in HIV-1-positive patients who initiated HAART at a CD4+ T-cell count >350 cells/mm...
  68. ncbi request reprint Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012)
    Mark A Boyd
    HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    J Infect Dis 194:1319-22. 2006
    ..62+/-0.34 per day and -0.51+/-0.16 per day; P>.1). Antiretroviral therapy that inhibits HIV reverse transcriptase and protease exerts potent antiviral effects that might not be augmented by the addition of an HIV fusion inhibitor...
  69. ncbi request reprint Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz
    Mark A Boyd
    HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    J Infect Dis 194:642-50. 2006
    ..Improvements in lipoatrophy after a switch in nucleoside reverse-transcriptase inhibitors (NRTIs) have been demonstrated. We investigated 60 patients switching from failed NRTIs to ritonavir-boosted indinavir and efavirenz...
  70. ncbi request reprint Long-term highly active antiretroviral therapy in chronic HIV-1 infection: evidence for reconstitution of antiviral immunity
    Christine A Jansen
    Department of Clinical Viro Immunology, Sanquin Research at CLB and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, The Netherlands
    Antivir Ther 11:105-16. 2006
    ....
  71. ncbi request reprint Are adverse events of nevirapine and efavirenz related to plasma concentrations?
    Bregt S Kappelhoff
    Department of Pharmacy Et Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands
    Antivir Ther 10:489-98. 2005
    ..The relationships between adverse events (AEs) and plasma concentrations of nevirapine (NVP) and efavirenz (EFV) were investigated as part of the large, international, randomized 2NN study...
  72. ncbi request reprint Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenz
    Frank van Leth
    Department of Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Antivir Ther 9:721-8. 2004
    ..To assess whether differences in safety profiles between nevirapine (NVP) and efavirenz (EFV), as observed in the 2NN study, translated into differences in 'health related quality of life' (HRQoL)...
  73. ncbi request reprint Nelfinavir plasma concentrations are low during pregnancy
    Jeannine F J B Nellen
    Academic Medical Center, Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine, and AIDS, Amsterdam, The Netherlands
    Clin Infect Dis 39:736-40. 2004
    ..After we adjusted for confounders, we found that the mean nelfinavir CR was 34% lower in pregnant women (P=.02). With targeted interventions, subsequent CRs in pregnant women showed a significant increase (median increase, 0.31; P=.01)...
  74. ncbi request reprint Low versus high CD4 cell count as starting point for introduction of antiretroviral treatment in resource-poor settings: a scenario-based analysis
    Johannes A Bogaards
    Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, The Netherlands
    Antivir Ther 8:43-50. 2003
    ..To evaluate CD4 cell count-driven strategies for the initiation of highly active antiretroviral therapy (HAART) in terms of the reduction of the incidence of AIDS-defining events in resource-poor settings...
  75. ncbi request reprint CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients
    Ferdinand W N M Wit
    Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, National AIDS Therapy Evaluation Centre, 1105 AZ Amsterdam, The Netherlands
    J Infect Dis 186:1726-32. 2002
    ....
  76. ncbi request reprint Prioritising access to antiretroviral therapy in resource-poor settings
    Joep M A Lange
    National AIDS Therapy Evaluation Centre, Academic Medical Centre, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    J HIV Ther 7:59-62. 2002
    ..However, both from a humanitarian and an economic and developmental perspective, we cannot afford not to bring highly active antiretroviral therapy (HAART) to these settings...
  77. ncbi request reprint The pharmacokinetics of nelfinavir in HIV-1-infected children
    Rolf P G van Heeswijk
    Dept of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands
    Ther Drug Monit 24:487-91. 2002
    ..However, due to a large interpatient variability in the exposure, individual dosage adjustments based on plasma concentrations may be necessary for both dosing regimens to ensure optimal treatment...
  78. ncbi request reprint Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy
    Ferdinand W N M Wit
    National AIDS Therapy Evaluation Center, Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, The Netherlands
    J Infect Dis 186:23-31. 2002
    ..In 97% of cases, >or=1 risk factor was present. In HBV-coinfected patients using 3TC, continued use of 3TC should be considered, even if 3TC-resistant HIV strains develop...
  79. ncbi request reprint Discordant responses during antiretroviral therapy: role of immune activation and T cell redistribution rather than true CD4 T cell loss
    Mette D Hazenberg
    Department of Clinical Viro Immunology, Sanquin Research, CLB and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, The Netherlands
    AIDS 16:1287-9. 2002
    ..Low reactivity to rebounding virus may preserve normal T lymphocyte distribution over blood and tissues and be associated with stable peripheral blood T cell numbers in virological failures to HAART...
  80. ncbi request reprint Persistence of viral HLA-DR- CD4 T-cell reservoir during prolonged treatment of HIV-1 infection with a five-drug regimen
    Ronald P Van Rij
    Department of Clinical Viro Immunology, CLB Sanquin and Landsteiner Laboratory of the Academic Medical Center, Amsterdam, The Netherlands
    Antivir Ther 7:37-41. 2002
    ..Strategies other than treatment with a combination of five of the currently available drugs need to be pursued in order to achieve eradication of HIV-1 from this cellular reservoir...
  81. ncbi request reprint Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression
    Jeanne P Dieleman
    Pharmaco epidemiology Unit, and Departments of Epidemiology and Biostatistics and Internal Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands
    J Infect Dis 185:1261-8. 2002
    ..In patients with virus suppression, a switch to Nvp is more likely than a switch to second-line PIs to result in sustained virus suppression and maintenance of the new regimen...
  82. ncbi request reprint Dose-escalating study of the safety and pharmacokinetics of nelfinavir in HIV-exposed neonates
    Chokechai Rongkavilit
    HIV Netherlands Australia Thailand Research Collaboration HIV NAT, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    J Acquir Immune Defic Syndr 29:455-63. 2002
    ..The highly variable systemic exposure observed in the study indicates that therapeutic drug monitoring seems warranted to ensure adequate NFV dosing in this population...
  83. ncbi request reprint Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia
    Jaap Goudsmit
    Department of Human Retrovirology, Division of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
    AIDS 16:791-3. 2002
  84. ncbi request reprint Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort
    Jeanne P Dieleman
    the Pharmaco Epidemiology Unit, Departments of Internal Medicine, and Epidemiology and Biostatistics, Erasmus University Medical Centre Rotterdam, Rotterdam, The Netherlands
    AIDS 16:737-45. 2002
    ..Toxicity is the most important reason for premature switching of highly active antiretroviral therapy (HAART). In order to optimize the benefit-risk ratio of HAART, guidelines for toxicity management are needed...
  85. ncbi request reprint Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy
    Rieneke M E van Praag
    National AIDS Therapy Evaluation Center NATEC, Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, University of Amsterdam, The Netherlands
    AIDS 16:719-25. 2002
    ..In a large percentage of such patients, more sensitive assays provide evidence of residual viral replication. The question is whether more potent therapy can further suppress this residual replication...
  86. ncbi request reprint Functional restoration of human immunodeficiency virus and Epstein-Barr virus-specific CD8(+) T cells during highly active antiretroviral therapy is associated with an increase in CD4(+) T cells
    Stefan Kostense
    Department of Clinical Viro Immunology, CLB and Laboratory for Experimental and Clinical Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Eur J Immunol 32:1080-9. 2002
    ..Overall, these data indicate that HAART improves the antigen responsiveness of both HIV- and EBV-specific T cells, which is associated with an increase in CD4(+) T cells...
  87. ncbi request reprint Dynamics of the pool of infected resting CD4 HLA-DR- T lymphocytes in patients who started a triple class five-drug antiretroviral regimen during primary HIV-1 infection
    Sanjay U C Sankatsing
    National AIDS Therapy Evaluation Center, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Antivir Ther 8:137-42. 2003
    ..Therefore, longer or even stronger suppression of viral replication might be necessary to achieve this goal in primary HIV-1 infection...
  88. ncbi request reprint Antiretroviral therapy and resistance to antiretroviral drugs
    Joep M A Lange
    International Antiviral Therapy Evaluation Centre IATEC, Academic Medical Center University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Ethiop Med J 40:51-75. 2002
    ..This paper presents an overview of antiretroviral therapy and resistance to antiretroviral drugs...
  89. ncbi request reprint Persistent immune activation in HIV-1 infection is associated with progression to AIDS
    Mette D Hazenberg
    Department of Clinical Viro Immunology, Sanquin Research at CLB, Tropical Medicine and AIDS, Amsterdam, The Netherlands
    AIDS 17:1881-8. 2003
    ..HIV-1 infection is characterized by chronic generalized CD8 and CD4 T cell hyperactivation, the biological effect of which is not understood...
  90. ncbi request reprint Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools
    Sanjay U C Sankatsing
    International Antiviral Therapy Evaluation Center, 1105 AZ Amsterdam, The Netherlands
    Clin Pharmacokinet 43:823-32. 2004
    ....
  91. ncbi request reprint Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients
    Sanjay U C Sankatsing
    Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, University of Amsterdam, The Netherlands
    AIDS 18:1925-31. 2004
    ..To study the effect of mycophenolate mofetil (MMF) on the decay rate of plasma HIV-1 RNA and the latently infected cellular reservoir in treatment-naive patients starting antiretroviral therapy...
  92. ncbi request reprint Establishment of the CD4+ T-cell pool in healthy children and untreated children infected with HIV-1
    Mette D Hazenberg
    Department of Clinical Viro Immunology, Sanquin Research at CLB, Amsterdam, The Netherlands
    Blood 104:3513-9. 2004
    ..We postulate that in children infected with HIV, similar to adults infected with HIV, continuous activation of naive T cells leads to erosion of the naive T-cell pool and may be a major factor in lowering CD4(+) T-cell numbers...
  93. ncbi request reprint Markedly diminished lipolysis and partial restoration of glucose metabolism, without changes in fat distribution after extended discontinuation of protease inhibitors in severe lipodystrophic human immunodeficient virus-1-infected patients
    Marc van der Valk
    International Antiviral Therapy Evaluation Center, Academic Medical Center, T0 120, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands
    J Clin Endocrinol Metab 89:3554-60. 2004
    ..In contrast, fasting glucose production and insulin-stimulated glucose oxidation improve moderately, whereas insulin-stimulated glucose disposal and fat distribution do not change...
  94. ncbi request reprint Is the male genital tract really a sanctuary site for HIV? Arguments that it is not
    Selwyn H Lowe
    Department of Internal Medicine, Tropical Medicine and AIDS, International Antiviral Therapy Evaluation Center IATEC, University of Amsterdam, Amsterdam, The Netherlands
    AIDS 18:1353-62. 2004
  95. ncbi request reprint Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection
    Chaiwat Ungsedhapand
    HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    J Acquir Immune Defic Syndr 36:693-701. 2004
    ..Triple-nucleoside therapy with ZDV, 3TC, and ddI or d4T, 3TC, and ABC in patients with HIV infection is more effective in inducing a sustained virologic response than the dual combinations of ZDV and 3TC or ddI and d4T...
  96. ncbi request reprint Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort
    W Phillip Law
    National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Darlinghurst, Sydney, Australia
    AIDS 18:1169-77. 2004
    ..To examine the impact of viral hepatitis co-infection on HIV disease outcomes following commencement of combination antiretroviral therapy in a developing country setting...
  97. ncbi request reprint Evaluation of nevirapine and/or hydroxyurea with nucleoside reverse transcriptase inhibitors in treatment-naive HIV-1-infected subjects
    Daniel H Blanckenberg
    International Antiviral Therapy Evaluation Center, Departmernt of Human Retrovirology, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    AIDS 18:631-40. 2004
    ..To examine the effect of adding nevirapine (NVP) and/or hydroxyurea (HU) to a triple nucleoside analogue reverse transcriptase inhibitor (NRTI) regimen in terms of efficacy and tolerability...
  98. pmc P glycoprotein in human immunodeficiency virus type 1 infection and therapy
    Sanjay U C Sankatsing
    Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Center, University of Amsterdam, The Netherlands
    Antimicrob Agents Chemother 48:1073-81. 2004
  99. ncbi request reprint TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen
    Sanjay U C Sankatsing
    Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    AIDS 17:2623-7. 2003
    ....
  100. ncbi request reprint Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects
    Mark A Boyd
    The HIV Netherlands Australia Thailand Research Collaboration, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    J Acquir Immune Defic Syndr 34:134-9. 2003
    ....
  101. ncbi request reprint Mortality and progression to AIDS after starting highly active antiretroviral therapy
    Ard I van Sighem
    HIV Monitoring Foundation, Academic Medical Centre of the University of Amsterdam, Amsterdam, The Netherlands
    AIDS 17:2227-36. 2003
    ..To examine survival and progression to AIDS among HIV-infected patients after starting highly active antiretroviral therapy (HAART)...